AI assistant
NLS Pharmaceutics Ltd. — Regulatory Filings 2021
Apr 5, 2021
35193_ffr_2021-04-05_2f04178f-b95d-4460-84a4-6114c323ad46.zip
Regulatory Filings
Open in viewerOpens in your device viewer
6-K 1 ea138964-6k_nlspharmaceutics.htm REPORT OF FOREIGN PRIVATE ISSUER
Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2021
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
Alter Postplatz 2
CH-6370 Stans, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
CONTENTS
Appointment of New Chief Operating Officer
On April 5, 2021, the Registrant announced that Silvia Panigone, Ph.D. has been appointed as the Chief Operating Officer of the Registrant.
A copy of the Registrant’s press release containing this announcement is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.
Field: Page; Sequence: 2; Options: NewSection; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence
Field: /Page
EXHIBIT INDEX
| Exhibit No. | |
|---|---|
| 99.1 | Press release titled: “NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer.” |
Field: Page; Sequence: 3; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| /s/ Alexander Zwyer | |
|---|---|
| Name: | Alexander Zwyer |
| Title: | Chief Executive Officer |
3
Field: Rule-Page
Field: /Rule-Page